Streamlining Bioconjugation for Antibody-Drug Conjugate Development

Bioconjugation plays a key role in creating antibody-drug conjugates (ADCs), offering precise linking of biologically active molecules with potent payloads.

Abzena specialize in cutting-edge bioconjugation methods that support the development of stable and effective ADCs. By leveraging proprietary technologies like ThioBridge™, we streamline the conjugation process, ensuring efficacy, safety, and scalability of your therapeutic.

Abzena supports every step of ADC development, from discovery through to manufacturing, with a focus on precision and efficiency.

Download our ‘Streamlining Bioconjugation for Antibody-Drug Conjugate Development’ info sheet today to discover how our expert team, technologies and platforms can de-risk and streamline your ADC development program to IND and beyond.

Download Info Sheet